Log in

NASDAQ:MGEN - Miragen Therapeutics Stock Price, Forecast & News

$0.97
+0.29 (+42.65 %)
(As of 01/27/2020 01:39 AM ET)
Today's Range
$0.73
Now: $0.97
$1.45
50-Day Range
$0.45
MA: $0.59
$0.97
52-Week Range
$0.44
Now: $0.97
$3.80
Volume21.25 million shs
Average Volume928,307 shs
Market Capitalization$30.84 million
P/E RatioN/A
Dividend YieldN/A
Beta1.36
Miragen Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing proprietary RNA-targeted therapies with a specific focus on microRNAs and their role in diseases where there is a high unmet medical need. Its three lead product candidates include cobomarsen, an inhibitor of miR-155 for treating various blood cancers, such as cutaneous T-cell lymphoma, adult T-cell lymphoma/leukemia, diffuse large B-cell lymphoma, and chronic lymphocytic leukemia; Remlarsen, a replacement for miR-29, a microRNA that is found at abnormally low levels in various pathological fibrotic conditions, including cutaneous, ocular, and idiopathic pulmonary fibrosis; and MRG-110, an inhibitor of miR-92, a microRNA expressed in endothelial cells for the treatment of heart failure, as well as surgical incisions in high risk populations, severe lacerations, and severe burns in the United States and Japan. Read More…

Industry, Sector and Symbol

Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:MGEN
CUSIPN/A
Phone720-643-5200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$8.39 million
Book Value$1.66 per share

Profitability

Net Income$-32,700,000.00
Net Margins-1,037.02%

Miscellaneous

Employees77
Market Cap$30.84 million
Next Earnings Date3/11/2020 (Estimated)
OptionableNot Optionable

Receive MGEN News and Ratings via Email

Sign-up to receive the latest news and ratings for MGEN and its competitors with MarketBeat's FREE daily newsletter.


Miragen Therapeutics (NASDAQ:MGEN) Frequently Asked Questions

What is Miragen Therapeutics' stock symbol?

Miragen Therapeutics trades on the NASDAQ under the ticker symbol "MGEN."

How were Miragen Therapeutics' earnings last quarter?

Miragen Therapeutics Inc (NASDAQ:MGEN) issued its earnings results on Thursday, November, 7th. The medical research company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.06. The medical research company earned $0.70 million during the quarter, compared to analysts' expectations of $1.67 million. Miragen Therapeutics had a negative return on equity of 113.02% and a negative net margin of 1,037.02%. View Miragen Therapeutics' Earnings History.

When is Miragen Therapeutics' next earnings date?

Miragen Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, March 11th 2020. View Earnings Estimates for Miragen Therapeutics.

What price target have analysts set for MGEN?

3 analysts have issued twelve-month price targets for Miragen Therapeutics' stock. Their forecasts range from $3.00 to $8.00. On average, they anticipate Miragen Therapeutics' stock price to reach $5.50 in the next year. This suggests a possible upside of 467.0% from the stock's current price. View Analyst Price Targets for Miragen Therapeutics.

What is the consensus analysts' recommendation for Miragen Therapeutics?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Miragen Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Miragen Therapeutics.

Has Miragen Therapeutics been receiving favorable news coverage?

Headlines about MGEN stock have been trending extremely negative this week, according to InfoTrie Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Miragen Therapeutics earned a coverage optimism score of -4.5 on InfoTrie's scale. They also assigned news coverage about the medical research company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the stock's share price in the near future. View News Stories for Miragen Therapeutics.

Are investors shorting Miragen Therapeutics?

Miragen Therapeutics saw a drop in short interest in the month of January. As of January 15th, there was short interest totalling 573,800 shares, a drop of 10.8% from the December 31st total of 643,500 shares. Based on an average daily volume of 478,700 shares, the short-interest ratio is currently 1.2 days. Approximately 2.2% of the company's shares are short sold. View Miragen Therapeutics' Current Options Chain.

Who are some of Miragen Therapeutics' key competitors?

What other stocks do shareholders of Miragen Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Miragen Therapeutics investors own include Opko Health (OPK), Alibaba Group (BABA), Bellicum Pharmaceuticals (BLCM), AbbVie (ABBV), Novavax (NVAX), Sorrento Therapeutics (SRNE), vTv Therapeutics (VTVT), Genocea Biosciences (GNCA), Inovio Pharmaceuticals (INO) and Rigel Pharmaceuticals (RIGL).

Who are Miragen Therapeutics' key executives?

Miragen Therapeutics' management team includes the folowing people:
  • Dr. William Stuart Marshall Ph.D., Co-Founder, Pres, CEO & Director (Age 55)
  • Mr. Adam Scott Levy, Chief Bus. Officer (Age 41)
  • Dr. Paul D. Rubin, Exec. VP of R&D (Age 65)
  • Eric N. Olson, Co-Founder & Chairman of Scientific Advisory Board
  • Dr. Michael R. Bristow, Co-Founder & Member of the Scientific Advisory Board (Age 74)

Who are Miragen Therapeutics' major shareholders?

Miragen Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Wedbush Securities Inc. (0.28%). Company insiders that own Miragen Therapeutics stock include Adam Scott Levy, Bruce Booth and Thomas E Hughes. View Institutional Ownership Trends for Miragen Therapeutics.

Which institutional investors are buying Miragen Therapeutics stock?

MGEN stock was bought by a variety of institutional investors in the last quarter, including Wedbush Securities Inc.. Company insiders that have bought Miragen Therapeutics stock in the last two years include Adam Scott Levy, Bruce Booth and Thomas E Hughes. View Insider Buying and Selling for Miragen Therapeutics.

How do I buy shares of Miragen Therapeutics?

Shares of MGEN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Miragen Therapeutics' stock price today?

One share of MGEN stock can currently be purchased for approximately $0.97.

How big of a company is Miragen Therapeutics?

Miragen Therapeutics has a market capitalization of $30.84 million and generates $8.39 million in revenue each year. The medical research company earns $-32,700,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. Miragen Therapeutics employs 77 workers across the globe.View Additional Information About Miragen Therapeutics.

What is Miragen Therapeutics' official website?

The official website for Miragen Therapeutics is http://www.signalgenetics.com/.

How can I contact Miragen Therapeutics?

Miragen Therapeutics' mailing address is 6200 LOOKOUT ROAD, BOULDER CO, 80301. The medical research company can be reached via phone at 720-643-5200 or via email at [email protected]


MarketBeat Community Rating for Miragen Therapeutics (NASDAQ MGEN)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  227 (Vote Outperform)
Underperform Votes:  199 (Vote Underperform)
Total Votes:  426
MarketBeat's community ratings are surveys of what our community members think about Miragen Therapeutics and other stocks. Vote "Outperform" if you believe MGEN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGEN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 1/27/2020 by MarketBeat.com Staff

Featured Article: Risk Tolerance

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel